{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Duchenne+Muscular+Dystrophy&page=3&q=exon+skipping",
    "query": {
      "q": "exon skipping",
      "condition": "Duchenne Muscular Dystrophy",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Duchenne+Muscular+Dystrophy&page=4&q=exon+skipping&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Duchenne+Muscular+Dystrophy&page=2&q=exon+skipping&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T18:08:21.653Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03907072",
      "title": "Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "WVE-210201 (suvodirsen)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wave Life Sciences USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "12 Years",
        "sex": "MALE",
        "summary": "5 Years to 12 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2019-09-04",
      "completion_date": "2020-01-09",
      "has_results": true,
      "last_update_posted_date": "2021-05-20",
      "last_synced_at": "2026-10-10T18:08:21.653Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Kansas City, Kansas + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03907072"
    },
    {
      "nct_id": "NCT02500381",
      "title": "Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "SRP-4045",
          "type": "DRUG"
        },
        {
          "name": "SRP-4053",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "13 Years",
        "sex": "MALE",
        "summary": "6 Years to 13 Years · Male only"
      },
      "enrollment_count": 228,
      "start_date": "2016-09-28",
      "completion_date": "2025-10-16",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-10-10T18:08:21.653Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02500381"
    },
    {
      "nct_id": "NCT04956289",
      "title": "Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Viltolarsen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NS Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "8 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2021-07-01",
      "completion_date": "2023-07-13",
      "has_results": true,
      "last_update_posted_date": "2024-08-20",
      "last_synced_at": "2026-10-10T18:08:21.653Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04956289"
    },
    {
      "nct_id": "NCT07608432",
      "title": "Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy (DMD)",
        "Muscular Dystrophy, Duchenne",
        "Muscular Dystrophy (DMD)",
        "DMD",
        "Muscular Dystrophies",
        "Muscular Dystrophy in Children",
        "Muscular Dystrophy, Duchenne Type",
        "Muscular Dystrophy, Duchenne and Becker Types",
        "Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)",
        "Genetic Disease, Inborn",
        "Genetic Disease, X-Linked",
        "Congenital, Hereditary, and Neonatal Diseases and Abnormalities",
        "Neuromuscular Diseases (NMD)"
      ],
      "interventions": [
        {
          "name": "Zeleciment Rostudirsen (DYNE-251)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dyne Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "4 Years to 18 Years · Male only"
      },
      "enrollment_count": 90,
      "start_date": "2026-06",
      "completion_date": "2032-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-10T18:08:21.653Z",
      "location_count": 1,
      "location_summary": "Hillsborough, North Carolina",
      "locations": [
        {
          "city": "Hillsborough",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07608432"
    },
    {
      "nct_id": "NCT01539772",
      "title": "Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Becker Muscular Dystrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cooperative International Neuromuscular Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "4 Years and older · Male only"
      },
      "enrollment_count": 85,
      "start_date": "2012-04",
      "completion_date": "2018-08",
      "has_results": false,
      "last_update_posted_date": "2018-06-15",
      "last_synced_at": "2026-10-10T18:08:21.653Z",
      "location_count": 13,
      "location_summary": "Sacramento, California • Washington D.C., District of Columbia • Gainesville, Florida + 10 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01539772"
    },
    {
      "nct_id": "NCT07250737",
      "title": "Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Muscular Disorders, Atrophic",
        "Muscular Diseases",
        "Musculoskeletal Diseases",
        "Neuromuscular Diseases",
        "Nervous System Diseases",
        "Genetic Diseases, Inborn",
        "Genetic Diseases, X-Linked",
        "Muscular Dystrophies",
        "Muscular Dystrophy, Duchenne"
      ],
      "interventions": [
        {
          "name": "delpacibart zotadirsen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "2 Years and older · Male only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-10T18:08:21.653Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Carlos",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07250737"
    },
    {
      "nct_id": "NCT07092540",
      "title": "The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Duchenne Muscular Dystrophy (DMD)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": "3 Years",
        "sex": "MALE",
        "summary": "0 Days to 3 Years · Male only"
      },
      "enrollment_count": 105,
      "start_date": "2026-06-03",
      "completion_date": "2029-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-10T18:08:21.653Z",
      "location_count": 4,
      "location_summary": "Rochester, New York • Stony Brook, New York • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07092540"
    },
    {
      "nct_id": "NCT05670730",
      "title": "Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy",
        "Exon 44"
      ],
      "interventions": [
        {
          "name": "AOC 1044",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "7 Years to 55 Years · Male only"
      },
      "enrollment_count": 70,
      "start_date": "2022-11-09",
      "completion_date": "2024-11-25",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-10-10T18:08:21.653Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05670730"
    },
    {
      "nct_id": "NCT02420379",
      "title": "Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy (DMD)"
      ],
      "interventions": [
        {
          "name": "eteplirsen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "MALE",
        "summary": "4 Years to 6 Years · Male only"
      },
      "enrollment_count": 33,
      "start_date": "2015-06-30",
      "completion_date": "2018-12-17",
      "has_results": true,
      "last_update_posted_date": "2021-01-25",
      "last_synced_at": "2026-10-10T18:08:21.653Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02420379"
    },
    {
      "nct_id": "NCT04179409",
      "title": "A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Amondys 45",
          "type": "DRUG"
        },
        {
          "name": "Exondys 51",
          "type": "DRUG"
        },
        {
          "name": "Vyondys 53",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kevin Flanigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "6 Months and older · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2020-02-18",
      "completion_date": "2023-09-01",
      "has_results": true,
      "last_update_posted_date": "2023-10-26",
      "last_synced_at": "2026-10-10T18:08:21.653Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04179409"
    }
  ]
}